Investment analysts at Royal Bank Of Canada assumed coverage on shares of Amgen Inc. (NASDAQ:AMGN) in a report released on Thursday, September 14th, Marketbeat Ratings reports. The brokerage set a “sector perform” rating and a $192.00 price target on the medical research company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of 3.36% from the stock’s current price.
A number of other analysts have also recently commented on the company. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $189.00 price objective on shares of Amgen in a research report on Friday, June 30th. BidaskClub raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Jefferies Group LLC reissued a “hold” rating and set a $180.00 price target on shares of Amgen in a report on Monday, May 22nd. Credit Suisse Group set a $177.00 price target on Amgen and gave the company a “hold” rating in a report on Friday, July 14th. Finally, Morgan Stanley upped their price objective on Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 13th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $186.14.
Shares of Amgen (AMGN) traded down 0.47% on Thursday, hitting $185.76. 2,275,630 shares of the stock traded hands. The stock has a 50 day moving average of $175.99 and a 200-day moving average of $169.31. The stock has a market cap of $135.54 billion, a PE ratio of 16.92 and a beta of 1.35. Amgen has a 1-year low of $133.64 and a 1-year high of $191.10.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the previous year, the business earned $2.84 earnings per share. The company’s revenue was up 2.1% on a year-over-year basis. On average, equities research analysts expect that Amgen will post $12.57 EPS for the current year.
Several institutional investors have recently bought and sold shares of the company. Bogart Wealth LLC boosted its position in shares of Amgen by 13.8% in the 2nd quarter. Bogart Wealth LLC now owns 3,181 shares of the medical research company’s stock worth $548,000 after purchasing an additional 385 shares in the last quarter. Intl Fcstone Inc. acquired a new stake in shares of Amgen in the 2nd quarter worth $1,769,000. Gs Investments Inc. acquired a new stake in shares of Amgen in the 2nd quarter worth $2,119,000. Lord Abbett & CO. LLC acquired a new stake in shares of Amgen in the 2nd quarter worth $14,175,000. Finally, United Bank VA boosted its position in shares of Amgen by 7.4% in the 2nd quarter. United Bank VA now owns 28,581 shares of the medical research company’s stock worth $4,923,000 after purchasing an additional 1,960 shares in the last quarter. 78.09% of the stock is owned by hedge funds and other institutional investors.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.